The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 

Coronary Drug Eluting Stents

XIENCE V Everolimus Eluting Coronary Stent System

Indications & Important Safety Information ››

 

banner

 

Healthcare Professionals

Healthcare Professionals

XIENCE V - a DES with superior* outcomes that can take your performance to new heights. Abbott's XIENCE V is truly a next-generation DES, combining the proven deliverability of the MULTI-LINK VISION stent platform with a Multi-layer Coating Technology and everolimus to deliver superior* outcomes for patients with coronary artery disease (CAD).

* XIENCE V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT II Angiographic  6 months follow-up, Serruys. P, EuroInterv 2006; 2:286-294. SPIRIT III Angiographic  8months follow-up, Gregg Stone, JAMA 2008; 299(16): 1903-1913. SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and data on file at Abbott Vascular.  


TAXUS, TAXUS Liberte, and TAXUS Express are registered trademarks of Boston Scientific  or its affiliates.

Proven Design

XIENCE V is the DES designed for deliverability, efficacy, and safety. Every element of the stent and delivery system has been evaluated to bring you a true next-generation DES.

thin struts for less injury Thin struts for less injury1
  • 0.0032" strut thickness2
  • Clinically proven MULTI-LINK VISION CoCr stent
  • World's #1 metallic stent3
 superb deliverability Superb deliverability
  • Low balloon outside the stent to reduce injury4, 5
 controlled release, low dose of everolimus Controlled release, low dose of everolimus
  • Cytostatic drug
 Multi-layer Coating Technology Multi-layer Coating Technology
  • Thin, durable

 

1Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-II) trial. JACC. 2003; 41(8).
2Manufacturer-reported strut thickness. Data on file at Abbott Vascular.
3Market Share data on file as of March 2012.
4Tests performed by and data on file at Abbott Vascular.
5Carter, A.J. Experimental evaluation of a short transitional edge protection balloon for intracoronary stent deployment. CCI. 2000;51:112-119.

Hospital Administrators

XIENCE V provides superior* outcomes.
Combining Abbott's strong legacy of leadership and innovation with excellent service and support, XIENCE V delivers a solution that you can deploy with confidence.


The best possible customer service
Abbott is dedicated to offering hospitals the support they need to find products and answer questions. Below are resources designed just for you.

Country Customer Service Contact Phone Number
Sweden +46 (0) 20 795 058
Finland +358 (0) 800  98011 
Norway +47 800 10801
Denmark +45 8088 1765
Austria +43 800 240 210
UK +44 (0) 800 973 246  
Italy +39 (0) 5299 1163
Spain +34 901100905
Germany +49 6441 870 757 38
France +33 820 20 43 43
Switzerland +41 41 766 44 88
Australia +61 1800 550 939
Hong Kong +852 2593 2265 (Primary contact)
+852 2593 2272 (Secondary contact)

 

*XIENCE V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and data on file at Abbott Vascular.  
TAXUS, TAXUS Liberte, TAXUS Express2 are registered trademarks of Boston Scientific  or its affiliates.

AP2936764-WBO Rev. A